KDM1A and cancer: As an alternative to chemical compound, peptide-based inhibitors, as analogues of H3K4 substrates playing a role of antagonist (e.g., inhibiting LSD1), or peptide competitors, which block the interaction of LSD1 with its transcription factors (leading to more selective activation of LSD1 target genes), are now being investigated in cancer therapies and could be also applied to OA.